{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:40Z","timestamp":1790352580881,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01514-x","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:34:07Z","timestamp":1778776447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CHIP clinics: a practical overview of structure and function"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1514_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ajh.70205","volume":"101","author":"AA Mangaonkar","year":"2026","unstructured":"Mangaonkar AA, Bolton KL, Patnaik MM. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2026 update on clinical associations and management recommendations. Am J Hematol. 2026;101:550\u201365.","journal-title":"Am J Hematol"},{"key":"1514_CR2","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"1514_CR3","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"1514_CR4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472\u20138.","journal-title":"Nat Med"},{"key":"1514_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/ng.2413","volume":"44","author":"L Busque","year":"2012","unstructured":"Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179\u201381.","journal-title":"Nat Genet"},{"key":"1514_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1514_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1514_CR8","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1016\/S2352-3026(25)00137-1","volume":"12","author":"K Kirschner","year":"2025","unstructured":"Kirschner K, Kusne Y, Cargo C, Patnaik MM. Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time. Lancet Haematol. 2025;12:e650\u2013e661.","journal-title":"Lancet Haematol"},{"key":"1514_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00277-026-06741-7","volume":"105","author":"SA Patel","year":"2026","unstructured":"Patel SA, Khedr S, Hutchinson L, Xie Y, Khouri MR, Cerny J, et al. Portraits of clonal hematopoiesis in DNMT3A\/TET2\/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia. Ann Hematol. 2026;105:15.","journal-title":"Ann Hematol"},{"key":"1514_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.","journal-title":"Nat Commun"},{"key":"1514_CR11","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/bjh.19423","volume":"204","author":"SA Patel","year":"2024","unstructured":"Patel SA, Gerber WK, Zheng R, Khanna S, Hutchinson L, Abel GA, et al. Natural history of clonal haematopoiesis seen in real-world haematology settings. Br J Haematol. 2024;204:1844\u201355.","journal-title":"Br J Haematol"},{"key":"1514_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"1514_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/CIRCULATIONAHA.123.064170","volume":"148","author":"JD Cochran","year":"2023","unstructured":"Cochran JD, Yura Y, Thel MC, Doviak H, Polizio AH, Arai Y, et al. Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction. Circulation. 2023;148:1165\u201378.","journal-title":"Circulation"},{"key":"1514_CR14","doi-asserted-by":"crossref","unstructured":"Flynn S, Schuermans A, Uddin MM, Nakao T, Viscosi V, Libby P, et al. Clonal hematopoiesis and incident heart failure. JAMA Cardiol. e254603.2025.","DOI":"10.1001\/jamacardio.2025.4603"},{"key":"1514_CR15","unstructured":"Liu J, Zhang N, Teng G, Tse G, Bai J, Lip GYH, et al. Clonal hematopoiesis of indeterminate potential and atrial fibrillation. Heart Rhythm. 2025:S1547\u20135271."},{"key":"1514_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.123.065597","volume":"149","author":"AE Lin","year":"2024","unstructured":"Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, et al. Clonal hematopoiesis of indeterminate potential with loss of Tet2 enhances risk for atrial fibrillation through Nlrp3 inflammasome activation. Circulation. 2024;149:1419\u201334.","journal-title":"Circulation"},{"key":"1514_CR17","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1093\/eurheartj\/ehae682","volume":"45","author":"JAJ Verdonschot","year":"2024","unstructured":"Verdonschot JAJ, Fuster JJ, Walsh K, Heymans SRB. The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy. Eur Heart J. 2024;45:4797\u2013807.","journal-title":"Eur Heart J"},{"key":"1514_CR18","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","volume":"55","author":"M Gu","year":"2023","unstructured":"Gu M, Kovilakam SC, Dunn WG, Marando L, Barcena C, Mohorianu I, et al. Multiparameter prediction of myeloid neoplasia risk. Nat Genet. 2023;55:1523\u201330.","journal-title":"Nat Genet"},{"key":"1514_CR19","doi-asserted-by":"publisher","unstructured":"Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin M, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023;2. https:\/\/doi.org\/10.1056\/evidoa2200310.","DOI":"10.1056\/evidoa2200310"},{"key":"1514_CR20","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2024024756","volume":"144","author":"Z Xie","year":"2024","unstructured":"Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, et al. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024;144:2033\u201344.","journal-title":"Blood"},{"key":"1514_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41586-023-05857-4","volume":"616","author":"WJ Wong","year":"2023","unstructured":"Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, et al. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023;616:747\u201354.","journal-title":"Nature"},{"key":"1514_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41591-024-02854-6","volume":"30","author":"C Vlasschaert","year":"2024","unstructured":"Vlasschaert C, Robinson-Cohen C, Chen J, Akwo E, Parker AC, Silver SA, et al. Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury. Nat Med. 2024;30:810\u20137.","journal-title":"Nat Med"},{"key":"1514_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood.2022015384","volume":"140","author":"M Agrawal","year":"2022","unstructured":"Agrawal M, Niroula A, Cunin P, McConkey M, Shkolnik V, Kim PG, et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022;140:1094\u2013103.","journal-title":"Blood"},{"key":"1514_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211872","volume":"218","author":"PG Kim","year":"2021","unstructured":"Kim PG, Niroula A, Shkolnik V, McConkey M, Lin AE, S\u0142abicki M, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021;218:e20211872.","journal-title":"J Exp Med"},{"key":"1514_CR25","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1182\/bloodadvances.2022008376","volume":"6","author":"T Sella","year":"2022","unstructured":"Sella T, Fell GG, Miller PG, Gibson CJ, Rosenberg SM, Snow C, et al. Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. Blood Adv. 2022;6:6151\u201361.","journal-title":"Blood Adv"},{"key":"1514_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nature23876","volume":"549","author":"M Agathocleous","year":"2017","unstructured":"Agathocleous M, Meacham CE, Burgess RJ, Piskounova E, Zhao Z, Crane GM, et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017;549:476\u201381.","journal-title":"Nature"},{"key":"1514_CR27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood.2024024962","volume":"144","author":"Z Xie","year":"2024","unstructured":"Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough KB, et al. High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations. Blood. 2024;144:2456\u201361.","journal-title":"Blood"},{"key":"1514_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41586-025-08980-6","volume":"642","author":"M Gozdecka","year":"2025","unstructured":"Gozdecka M, Dudek M, Wen S, Gu M, Stopforth RJ, Rak J, et al. Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis. Nature. 2025;642:431\u201341.","journal-title":"Nature"},{"key":"1514_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-025-08871-w","volume":"642","author":"M Hosseini","year":"2025","unstructured":"Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, et al. Metformin reduces the competitive advantage of Dnmt3a(R878H) HSPCs. Nature. 2025;642:421\u201330.","journal-title":"Nature"},{"key":"1514_CR30","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.jacc.2025.08.025","volume":"86","author":"N Mohammadnia","year":"2025","unstructured":"Mohammadnia N, Xue L, Vestjens LTW, Uddin MM, Niroula A, de Kleijn DPV, et al. Colchicine and longitudinal dynamics of clonal hematopoiesis: an exploratory substudy of the LoDoCo2 trial. J Am Coll Cardiol. 2025;86:1983\u201396.","journal-title":"J Am Coll Cardiol"},{"key":"1514_CR31","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505.","journal-title":"N Engl J Med"},{"key":"1514_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","volume":"7","author":"EC Svensson","year":"2022","unstructured":"Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 2022;7:521\u20138.","journal-title":"JAMA Cardiol"},{"key":"1514_CR33","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","volume":"7","author":"J Woo","year":"2023","unstructured":"Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, et al. Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv. 2023;7:7471\u201384.","journal-title":"Blood Adv"},{"key":"1514_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1940-6207.CAPR-23-0342","volume":"17","author":"J Woo","year":"2024","unstructured":"Woo J, Zhai T, Yang F, Xu H, Healey ML, Yates DP, et al. Effect of clonal hematopoiesis mutations and canakinumab treatment on incidence of solid tumors in the CANTOS randomized clinical trial. Cancer Prev Res. 2024;17:429\u201336.","journal-title":"Cancer Prev Res"},{"key":"1514_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01531-8","volume":"17","author":"J Li","year":"2025","unstructured":"Li J, Chen R, Zhou J, Li N, Zhou P, Liu C, et al. Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction. Genome Med. 2025;17:94.","journal-title":"Genome Med"},{"key":"1514_CR36","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398.","journal-title":"N Engl J Med"},{"key":"1514_CR37","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331.","journal-title":"N Engl J Med"},{"key":"1514_CR38","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","volume":"8","author":"CD DiNardo","year":"2024","unstructured":"DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, et al. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome. Blood Adv. 2024;8:4209\u201320.","journal-title":"Blood Adv"},{"key":"1514_CR39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood-2025-635","volume":"146","author":"K Bolton","year":"2025","unstructured":"Bolton K, Madanat Y, Chandhok N, Sallman D, Singh A, Vij K, et al. Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: a phase II decentralized clinical trial. Blood. 2025;146:635.","journal-title":"Blood"},{"key":"1514_CR40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood.2023022260","volume":"143","author":"W Liu","year":"2024","unstructured":"Liu W, Pircher J, Schuermans A, Ul Ain Q, Zhang Z, Honigberg MC, et al. Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood. 2024;143:1539\u201350.","journal-title":"Blood"},{"key":"1514_CR41","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2025.3593","volume":"11","author":"LTP Thao","year":"2025","unstructured":"Thao LTP, Nguyen TL, Singh J, Byars SG, Bick AG, Ford L, et al. Low-dose aspirin for individualized cancer prevention in older adults: a secondary analysis of the ASPREE randomized clinical trial. JAMA Oncol. 2025;11:1348\u201355.","journal-title":"JAMA Oncol"},{"key":"1514_CR42","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamacardio.2025.3756","volume":"10","author":"ZK McQuilten","year":"2025","unstructured":"McQuilten ZK, Thao LTP, Bick AG, Byars S, Chan AT, Ford L, et al. Clonal hematopoiesis and cardiovascular disease and bleeding risk and the effectiveness of aspirin. JAMA Cardiol. 2025;10:1257\u201366.","journal-title":"JAMA Cardiol"},{"key":"1514_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood.2023019964","volume":"143","author":"MA Fabre","year":"2024","unstructured":"Fabre MA, Vassiliou GS. The lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia. Blood. 2024;143:573\u201381.","journal-title":"Blood"},{"key":"1514_CR44","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/bjh.19948","volume":"206","author":"SA Patel","year":"2025","unstructured":"Patel SA, Weeks LD. Drafting a blueprint for designing successful clinical trials in clonal haematopoiesis. Br J Haematol. 2025;206:800\u20132.","journal-title":"Br J Haematol"},{"key":"1514_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","volume":"4","author":"L Dorsheimer","year":"2019","unstructured":"Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25\u201333.","journal-title":"JAMA Cardiol"},{"key":"1514_CR46","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati L, Gall\u00ec A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371\u20138.","journal-title":"Blood"},{"key":"1514_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.12099","volume":"160","author":"C Nielsen","year":"2013","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol. 2013;160:70\u20139.","journal-title":"Br J Haematol"},{"key":"1514_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s44161-022-00206-6","volume":"2","author":"SM Zekavat","year":"2023","unstructured":"Zekavat SM, Viana-Huete V, Matesanz N, Jorshery SD, Zuriaga MA, Uddin MM, et al. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nat Cardiovasc Res. 2023;2:144\u201358.","journal-title":"Nat Cardiovasc Res"},{"key":"1514_CR49","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/ng.2700","volume":"45","author":"A Bonnefond","year":"2013","unstructured":"Bonnefond A, Skrobek B, Lobbens S, Eury E, Thuillier D, Cauchi S, et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet. 2013;45:1040\u20133.","journal-title":"Nat Genet"},{"key":"1514_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood.2021013531","volume":"139","author":"PG Miller","year":"2022","unstructured":"Miller PG, Qiao D, Rojas-Quintero J, Honigberg MC, Sperling AS, Gibson CJ, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022;139:357\u201368.","journal-title":"Blood"},{"key":"1514_CR51","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1200\/JCO.22.00857","volume":"41","author":"R Tian","year":"2023","unstructured":"Tian R, Wiley B, Liu J, Zong X, Truong B, Zhao S, et al. Clonal Hematopoiesis and Risk of Incident Lung Cancer. J Clin Oncol. 2023;41:1423\u201333.","journal-title":"J Clin Oncol"},{"key":"1514_CR52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1681\/ASN.2021060774","volume":"33","author":"C Vlasschaert","year":"2022","unstructured":"Vlasschaert C, McNaughton AJM, Chong M, Cook EK, Hopman W, Kestenbaum B, et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol. 2022;33:985\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1514_CR53","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41591-023-02397-2","volume":"29","author":"H Bouzid","year":"2023","unstructured":"Bouzid H, Belk JA, Jan M, Qi Y, Sarnowski C, Wirth S, et al. Clonal hematopoiesis is associated with protection from Alzheimer\u2019s disease. Nat Med. 2023;29:1662\u201370.","journal-title":"Nat Med"},{"key":"1514_CR54","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41375-023-02023-7","volume":"37","author":"C Vlasschaert","year":"2023","unstructured":"Vlasschaert C, Akwo E, Robinson-Cohen C, Cook EK, Lanktree MB, Rauh MJ, et al. Infection risk associated with clonal hematopoiesis of indeterminate potential is partly mediated by hematologic cancer transformation in the UK Biobank. Leukemia. 2023;37:2306\u20138.","journal-title":"Leukemia"},{"key":"1514_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26138-6","volume":"12","author":"KL Bolton","year":"2021","unstructured":"Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021;12:5975.","journal-title":"Nat Commun"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01514-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:04:57Z","timestamp":1783483497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01514-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01514-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SAP reports serving on Myelodysplastic Syndromes and\/or Acute Leukemia Advisory Boards for Bristol Myers Squibb, Syndax, and Taiho. AM reports research funding to institution for trials from BMS, Novartis, Medexus, Sanofi, and Solu Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}